/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 218 - JD Finley & Mitch Jones - Palisade Bio
Episode 218 - JD Finley & Mitch Jones - Palisade Bio

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix · Aug 31, 2026

Palisade Bio's PALI-2108 is a novel PDE4 inhibitor for IBD that uses local bio-activation to improve tolerability and efficacy. Phase 2 begins soon.

Single-Asset Biotechs Should Plan for a Future as a "Backbone Therapy"

Despite being a single-asset company, Palisade is strategically planning for the future of IBD treatment, which they believe will involve oral combination therapies. By positioning their well-tolerated drug as an ideal "backbone therapy," they create a long-term strategic narrative for partnership and market relevance beyond monotherapy use.

Episode 218 - JD Finley & Mitch Jones - Palisade Bio thumbnail

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix·3 months ago

Palisade Bio Pivoted a Failed Program by Hiring a CMO Who Brought His Own Asset

After their lead program failed, Palisade Bio was in the process of hiring a Chief Medical Officer. The candidate, Mitch Jones, proposed acquiring an asset he had been following. This serendipitous hire led to a complete company pivot, demonstrating how strategic talent acquisition can redefine a company's trajectory.

Episode 218 - JD Finley & Mitch Jones - Palisade Bio thumbnail

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix·3 months ago

Palisade Bio's IBD Drug Was Engineered for the Disease, Not Repurposed from a Platform

Unlike many assets discovered via platforms and then matched to an indication, Palisade's PDE4 inhibitor was specifically designed for Inflammatory Bowel Disease (IBD) from the start. This "disease-first" approach creates inherent mechanistic benefits and a stronger product narrative compared to repurposed drugs.

Episode 218 - JD Finley & Mitch Jones - Palisade Bio thumbnail

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix·3 months ago

Rapid Symptom Relief Is a Key Patient-Centric Differentiator in Chronic Disease

Beyond clinical endpoints, Palisade Bio emphasizes how quickly patients feel relief from IBD symptoms. They recognize that patients value immediate improvement and want to avoid trading disease discomfort for drug side effects. This patient-centric focus is a powerful differentiator in a crowded therapeutic area.

Episode 218 - JD Finley & Mitch Jones - Palisade Bio thumbnail

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix·3 months ago

Local Bio-Activation Solves Systemic Drug Tolerability Issues in IBD Treatment

To overcome the notorious tolerability issues of systemic PDE4 inhibitors, Palisade's drug is an oral prodrug activated by microbiome enzymes in the colon. This delivers high concentration directly to diseased tissue while maintaining a stable, lower systemic concentration, dramatically improving the therapeutic index and reducing adverse events.

Episode 218 - JD Finley & Mitch Jones - Palisade Bio thumbnail

Episode 218 - JD Finley & Mitch Jones - Palisade Bio

The BioHub - by Avetix·3 months ago